Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson

Generated: September 19, 2019

DrugPatentWatch Database Preview

Patent: 9,352,039

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,352,039
Title:Method of reducing the number of EMT and MET type breast cancer stem cells
Abstract: Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24-, EpCam-CD49P+ (for EMT cancers stem cells), ALDH+ and EPCam+CD49r- (for MET cancers stem cells), and CD44+CD24-ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).
Inventor(s): Liu; Suling (Heifei, CN), Wicha; Max S. (Ann Arbor, MI)
Application Number:14/376,923
Patent Claims:see list of patent claims

Details for Patent 9,352,039

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up 2032-02-09 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.